San Diego, CA, August 19, 2014 --(PR.com
)-- Epitope Diagnostics is proud to introduce a new adrenocortocotropic hormone (ACTH) ELISA Kit, which measures ACTH levels with high sensitivity and robust assay performance characteristics.
The ELISA (enzyme-linked immunosorbent assay) platform is a popular method for accurate detection of various molecules. It is relatively easy to perform, inexpensive, and does not require specialized equipment, making it easy to perform in clinical laboratories of all sizes. One drawback, however, is that current ACTH ELISA kits on the market are 4-hour tests. Long incubation periods decrease the efficiency of the laboratory and occupy space in automated ELISA systems.
Epitope Diagnostics has put great effort into the development of a simplified, robust, 2-hour ACTH assay with a high analytical sensitivity (LLOD: 0.4 pg/mL) and dynamic range. The assay procedure essentially remains unchanged except for the shorter incubation period, making this an easy transition for laboratory staff.
ACTH levels outside the normal range is associated with of many different diseases, such as Addison’s disease, congenital adrenal hyperplasia, Cushing’s syndrome, multiple endocrine neoplasia type I, and hypopituitarism, thereby making it an important marker in the research and diagnosis of these diseases.
About Epitope Diagnostics, Inc.
Established since 2003, Epitope Diagnostics, Inc. is an ISO 13845 certified medical device manufacturing company located in the Sorrento Valley biotech hub of San Diego, California. They specialize in development and manufacture of products for the global medical device and diagnostics industry. Their areas of interest include gastrointestinal, cardiovascular, infectious and autoimmune disease, as well as tumors/cancers and calcium/bone metabolism.